EX-99.2 4 dp05113e_ex9902.htm Unassociated Document
                                                                                  
 
   EXHIBIT 99.02 
 
Notification of major interests in shares
 
22 March 2007
 
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Shire plc

2. Reason for the notification
State
Yes/No
An acquisition or disposal of voting rights
 
An acquisition or disposal of financial instruments which may result in the
acquisition of shares already issued to which voting rights are attached
 
An event changing the breakdown of voting rights
  
Other (please specify): Revised due to DTR rules - see Section 13
Yes

3. Full name of person(s) subject to the notification obligation:
FMR Corp
4. Full name of shareholder(s) (if different from 3.):
See attached schedule
5. Date of the transaction (and date on which the threshold is crossed
or reached if different):
Revised due to DTR rules
6. Date on which issuer notified:
22 March 2007
7. Threshold(s) that is/are crossed or reached:
N/A
8. Notified details:
 


A: Voting rights attached to shares

Class/type of shares
if possible using the ISIN CODE
Situation previous to
the Triggering
transaction
Resulting situation after the triggering
transaction
 
Number
of
Shares
Number
of
Voting
Rights
Number
of
shares
Number of voting
rights
% of voting
rights
 
 
 
 
     
Direct
Direct
Indirect
Direct
Indirect
GB00B0KQX869
16,231,254
16,231,254
 
 
16,231,254
 
2.92%%
               
               

B: Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument
Expiration
date
Exercise/Conversion
Period/ Date
Number of voting
rights that may be
acquired if the instrument
is exercised/converted
% of voting
rights
 
 
 
 
 


Total (A+B)
  
Number of voting rights
% of voting rights
16,231,254
2.92%


9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are
effectively held, if applicable:

See attached schedule
 

Proxy Voting:


10. Name of the proxy holder:
FMR Corp
11. Number of voting rights proxy holder will cease to hold:
N/A
12. Date on which proxy holder will cease to hold voting rights:
N/A

13. Additional information:
As discussed with the FSA, prior to the implementation of the EU Transparency Directive, we aggregated the interests in the shares of FMR Corp (FMR) and Fidelity International Limited (FIL) together for the purposes of shareholder reporting. According to the new DTR rules we are now reporting the indirect holdings of FMR and FIL separately. A separate notification is being submitted for FIL. Please note these holdings are correct as of close of business 20 March 2007.
14. Contact name:
Sophie Hughes
15. Contact telephone number:
fil-regulatoryreporting@uk.fid-intl.com

(Contact at Shire plc: Vivienne Hemming, Deputy Company Secretary, 01256 894276)

Schedule:

Shares Held Nominee Management Company
 
 
 
846,920
173,000
30,380
99,054
19,300
107,400
45,400
64,300
79,300
98,300
10,026,900
4,474,900
36,100
130,000
STATE STREET BANK AND TR CO
STATE STREET BANK AND TR CO
STATE STREET BANK AND TR CO
STATE STREET BANK AND TR CO
NORTHERN TRUST LONDON
NORTHERN TRUST CO
MELLON BANK N.A.
MELLON BANK N.A.
JPMORGAN CHASE BANK
JPMORGAN CHASE BANK
JPMORGAN CHASE BANK
BROWN BROTHERS HARRIMAN AND CO
BANK OF NEW YORK
BANK OF NEW YORK
FMTC
FMRCO
FMR
FICL
FMRCO
FMTC
FMTC
FMRCO
FPM
FMTC
FMRCO
FMRCO
FMRCO
FMTC
 
FMR Corp is the parent holding company of Fidelity Management and Research Company (FMRCO), investment manager for US mutual funds and Fidelity Management Trust Company (FMTC), a US state chartered bank which acts as trustee or investment manager of various pension and trust accounts.

For further information please contact:

Investor Relations
Cléa Rosenfeld (Rest of the World)
+44 1256 894 160
 
Eric Rojas (North America)
+1 484 595 8252

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.